Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions.

Albrecht, J Mark; Cooper, Benjamin R; Waller, Jacquelyn D; Presley, Colby L; Pulsipher, Kayd J; Rundle, Chandler W; Dellavalle, Robert P

Albrecht, J Mark; Cooper, Benjamin R; Waller, Jacquelyn D; Presley, Colby L; Pulsipher, Kayd J; Rundle, Chandler W; Dellavalle, Robert P.

Afiliação

Dellavalle RP; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA Dermatology Service, U.S. Department of Veterans Affairs Rocky Mountain Regional Medical Center, Aurora, Colorado, USA. Robert.dellavalle@ucdenver.edu.

Dermatol Online J ; 29(1)2023 Feb 15.

Article em En | MEDLINE | ID: mdl-37040906

RESUMO

Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.

Assuntos

COVID-19; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Humanos; Ritonavir; Lactamas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / COVID-19 Limite: Humans Idioma: En Revista: Dermatol Online J Assunto da revista: DERMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google